Melanoma sensitivity

Publikationen

2018

Del Mistro, G., Lucarelli, P., Muller, I., De Landtsheer, S., Zinoveva, A., Hutt, M., Siegemund, M., Kontermann, R. E., Beissert, S., Sauter, T.Kulms, D., 2018. Systemic network analysis identifies XIAP and IkappaBalpha as potential drug targets in TRAIL resistant BRAF mutated melanoma. NPJ Syst Biol Appl, 4, 39. doi.org/10.1038/s41540-018-0075-y

Kuske, M., Westphal, D., Wehner, R., Schmitz, M., Beissert, S., Praetorius, C.Meier, F., 2018. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Pharmacol. Res., 136, 151-159. doi.org/10.1016/j.phrs.2018.08.019

Müller, I.Kulms, D., 2018. A 3D Organotypic Melanoma Spheroid Skin Model. J Vis Exp, (135). doi.org/10.3791/57500

Rozanc, J., Sakellaropoulos, T., Antoranz, A., Gutta, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., Kulms, D., Rehm, M.Alexopoulos, L. G., 2018. Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma. Cell Death Differ. doi.org/10.1038/s41418-018-0210-8

Siegemund, M., Schneider, F., Hutt, M., Seifert, O., Müller, I., Kulms, D., Pfizenmaier, K.Kontermann, R. E., 2018. IgG-single-chain TRAIL fusion proteins for tumour therapy. Sci Rep, 8(1), 7808. doi.org/10.1038/s41598-018-24450-8

2017

De Landtsheer, S., Trairatphisan, P., Lucarelli, P., Sauter, T., 2017. FALCON: a toolbox for the fast contextualization of logical networks. Bioinformatics 33, 3431–3436. doi.org/10.1093/bioinformatics/btx380

Hutt, M., Marquardt, L., Seifert, O., Siegemund, M., Müller, I., Kulms, D., Pfizenmaier, K., Kontermann, R.E., 2017. Superior Properties of Fc-comprising scTRAIL Fusion Proteins. Mol. Cancer Ther. 16, 2792–2802. doi.org/10.1158/1535-7163.MCT-17-0551

Niessner, H., Sinnberg, T., Kosnopfel, C., Smalley, K.S.M., Beck, D., Praetorius, C., Mai, M., Beissert, S., Kulms, D., Schaller, M., Garbe, C., Flaherty, K.T., Westphal, D., Wanke, I., Meier, F., 2017. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Clin. Cancer Res. 23, 6203–6214. doi.org/10.1158/1078-0432.CCR-17-0098

2016

Albrecht, M., Sciumè, G., Lucarelli, P., Sauter, T., 2016. Thermodynamically constrained averaging theory for cancer growth modelling*. IFAC-PapersOnLine, Foundations of Systems Biology in Engineering - FOSBE 2016Magdeburg, Germany, 9—12 October 2016 49, 289–294. doi.org/10.1016/j.ifacol.2016.12.141

Niessner, H., Schmitz, J., Tabatabai, G., Schmid, A.M., Calaminus, C., Sinnberg, T., Weide, B., Eigentler, T.K., Garbe, C., Schittek, B., Quintanilla-Fend, L., Bender, B., Mai, M., Praetorius, C., Beissert, S., Schackert, G., Muders, M.H., Meinhardt, M., Baretton, G.B., Dummer, R., Flaherty, K., Pichler, B.J., Kulms, D., Westphal, D., Meier, F., 2016. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. Clin. Cancer Res. 22, 5818–5828. doi.org/10.1158/1078-0432.CCR-16-0064

Melanoma Sensitivity-Projekte in den Medien: